[A combination chemotherapy using mitomycin C, vincristine and cisplatin (MVP) for advanced cervical cancer]

Nine patients with advanced cervical cancer were treated with a combination chemotherapy (MVP) consisting of mitomycin C 8 mg/m2 i.v. days 1 and 8, vincristine 1 mg/m2 i.v. days 1 and 8, and cisplatin 15 mg/m2 i.v. days 1 to 5. The regimen was repeated at 4-week intervals. Of nine patients with measurable metastatic disease, there was 1 complete response (CR), 4 partial responses (PR), and 4 with no change, with an overall response rate (CR + PR) of 56% (5/9). The median duration of responses was 6 months, ranging from 1.8 to 9.1 months. The median survival time from initiation of the chemotherapy was 11 months for responders, and 15+ months for non-responders, respectively. Patients with no prior chemotherapy had a 60% (3/5) response rate and 2 patients out of 4 who had received prior chemotherapy responded; furthermore, metastatic lesions in extrapelvic regions (lung) responded well. Leukopenia less than 3,000/mm3 occurred in 68% of cases and the median nadir was 1,900/mm3 (700-2900). Thrombocytopenia less than 10 X 10/mm3 occurred in 37% of cases and the median nadir was 5.15 X 10/mm3 (3.2-9.0). Non-hematological toxicities were nausea and vomiting, renal dysfunction and peripheral neuropathy, but these were reversible and tolerable.